VEGFA and pathological myopia: Ranibizumab and Conbercept are both effective anti-VEGF agents commonly used in treating retinal diseases such as CNV, diabetic macular edema (DME), retinal vein occlusion (RVO), and pathologic myopia (PM) [34–36].